Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).

Bibliographic Details
Main Authors:	Lundin, J, Kimby, E, Bjorkholm, M, Celsing, F, Hale, G, Hjalmar, V, Merup, M, Petrescu, A, Tullgren, O, Waldmann, H, Mellstedt, H, Osterborg, A
Format:	Journal article
Published:	2001

Similar Items

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
by: Lundin, J, et al.
Published: (2002)

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
by: Hale, G, et al.
Published: (2004)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
by: Hale, G, et al.
Published: (2002)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
by: Chakrabarti, S, et al.
Published: (2004)

In vivo 'purging' of residual disease in CLL with Campath-1H.
by: Dyer, M, et al.
Published: (1997)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
by: Watson, C, et al.
Published: (2004)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
by: Clatworthy, MR, et al.
Published: (2009)

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
by: Watson, C, et al.
Published: (2005)

CAMPATH: from concept to clinic.
by: Waldmann, H, et al.
Published: (2005)

Alemtuzumab (Campath-1H) para tratamento da leucemia linfóide crônica
by: Maria Kadma da Silva Carriço, et al.
Published: (2003-06-01)

Specificity of monoclonal antibody Campath-1.
by: Hale, G, et al.
Published: (1988)

Availability of Campath-1 antibodies for bone marrow transplantation.
by: Hale, G, et al.
Published: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
by: Hale, G, et al.
Published: (1994)

The CAMPATH-1 antigen (CDw52).
by: Hale, G, et al.
Published: (1990)

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL
by: Munir, T, et al.
Published: (2014)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
by: Hale, G, et al.
Published: (1988)

CAMPATH-1H in inflammatory arthritis.
by: Watts, R, et al.
Published: (1993)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
by: Hale, G, et al.
Published: (1996)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
by: Waldmann, H, et al.
Published: (1987)

S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: O. Al-Sawaf, et al.
Published: (2022-06-01)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
by: Othman Al-Sawaf, et al.
Published: (2023-08-01)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
by: Lim, S, et al.
Published: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
by: Novitzky, N, et al.
Published: (2004)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
by: Xia, M, et al.
Published: (1993)

CAMPATH-IH in multiple sclerosis.
by: Moreau, T, et al.
Published: (1996)

CAMPATH-1 antibodies in stem-cell transplantation.
by: Hale, G, et al.
Published: (2001)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
by: Waldmann, H, et al.
Published: (1985)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
by: Williams, R, et al.
Published: (2000)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
by: Dyer, M, et al.
Published: (1989)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
by: Lim, S, et al.
Published: (1993)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
by: Dyer, M, et al.
Published: (1988)

A personal history of the CAMPATH-1H antibody.
by: Waldmann, H
Published: (2002)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
by: Waldmann, H, et al.
Published: (1985)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
by: Watts, R, et al.
Published: (1992)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
by: Hale, G, et al.
Published: (1998)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
by: Dyer, M, et al.
Published: (1989)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
by: Dyer, M, et al.
Published: (1990)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
by: Killick, S, et al.
Published: (1997)

Campath-1H therapy in refractory ocular inflammatory disease.
by: Dick, A, et al.
Published: (2000)

CAMPATH-1 FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE AND GRAFT-REJECTION - SUMMARY OF RESULTS FROM A MULTI-CENTRE STUDY
by: Hale, G, et al.
Published: (1988)